10,000 Shares of Moderna, Inc. $MRNA Purchased by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) during the third quarter, HoldingsChannel reports. The firm acquired 10,000 shares of the company’s stock, valued at approximately $1,926,000. Moderna comprises about 1.2% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 29th largest holding.

Several other hedge funds and other institutional investors have also made changes to their positions in MRNA. NorthCrest Asset Manangement LLC purchased a new stake in Moderna during the third quarter worth approximately $234,000. Gallagher Capital Advisors LLC acquired a new position in Moderna in the third quarter valued at approximately $2,244,000. Wedmont Private Capital boosted its holdings in Moderna by 55.4% in the third quarter. Wedmont Private Capital now owns 5,938 shares of the company’s stock valued at $1,170,000 after purchasing an additional 2,116 shares in the last quarter. Breakwater Capital Group acquired a new stake in Moderna during the third quarter worth approximately $304,000. Finally, Gainplan LLC purchased a new stake in shares of Moderna during the 3rd quarter worth approximately $482,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of several research analyst reports. Piper Sandler upped their target price on shares of Moderna from $77.00 to $167.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. CLSA upgraded shares of Moderna to an “outperform” rating in a research note on Friday, August 28th. The Goldman Sachs Group lifted their price target on shares of Moderna from $67.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 19th. Brookline Capital Markets reissued a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Finally, William Blair began coverage on shares of Moderna in a research note on Friday, August 28th. They issued an “outperform” rating for the company. Seven equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $100.60.

Insider Buying and Selling

In other Moderna news, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares in the company, valued at approximately $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 118,882 shares of company stock worth $16,862,280 in the last 90 days. Company insiders own 10.80% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Reports of encouraging results for Moderna’s mRNA cancer vaccine, along with a proposed NIH-backed initiative to accelerate personalized cancer-vaccine research, have strengthened expectations for the company’s oncology pipeline. Vaccine stocks, including MRNA, rallied on the news. Moderna Is Now Worth More Than 3X as Much as BioNTech Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
• Positive Sentiment: Health Canada is reviewing Moderna’s new mRNA flu vaccine, which could potentially reduce hospitalizations and provide another commercial growth opportunity beyond COVID-19 products. Health Canada reviewing new mRNA flu vaccine
• Neutral Sentiment: Moderna will report third-quarter 2026 results and provide a corporate update on November 6. The announcement itself does not change fundamentals, but investors may look for updates on revenue trends, cash usage and pipeline milestones. Moderna to Report Third Quarter 2026 Financial Results
• Negative Sentiment: The recent surge has prompted profit-taking and renewed valuation concerns. Moderna’s earlier Nasdaq-100 inclusion helped drive demand, but that event-driven buying may have faded, leaving the stock vulnerable to volatility. Moderna slides as investors reassess near-term catalysts
• Negative Sentiment: Reported insider activity shows selling rather than buying by several executives over the past six months, while several analysts’ price targets remain well below the current market valuation. These signals could limit gains if pipeline optimism weakens.

Moderna Stock Performance

NASDAQ MRNA traded up $1.83 on Tuesday, reaching $215.57. The stock had a trading volume of 8,068,334 shares, compared to its average volume of 12,221,597. The stock has a market cap of $86.07 billion, a P/E ratio of -26.99 and a beta of 1.09. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $227.46. The business’s 50-day moving average price is $143.25 and its 200 day moving average price is $86.30. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29.

Moderna (NASDAQ:MRNA) last announced its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. The business had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the firm posted ($2.13) earnings per share. As a group, equities analysts expect that Moderna, Inc. will post -6.11 earnings per share for the current year.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease, supporting the company’s work across infectious diseases, immuno-oncology, rare diseases, autoimmune conditions, and cardiovascular diseases.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.